全文获取类型
收费全文 | 23066篇 |
免费 | 1692篇 |
国内免费 | 51篇 |
专业分类
耳鼻咽喉 | 230篇 |
儿科学 | 923篇 |
妇产科学 | 596篇 |
基础医学 | 3119篇 |
口腔科学 | 682篇 |
临床医学 | 2632篇 |
内科学 | 4487篇 |
皮肤病学 | 344篇 |
神经病学 | 1823篇 |
特种医学 | 1002篇 |
外科学 | 3108篇 |
综合类 | 412篇 |
一般理论 | 43篇 |
预防医学 | 2153篇 |
眼科学 | 347篇 |
药学 | 1424篇 |
1篇 | |
中国医学 | 18篇 |
肿瘤学 | 1465篇 |
出版年
2022年 | 143篇 |
2021年 | 340篇 |
2020年 | 240篇 |
2019年 | 378篇 |
2018年 | 406篇 |
2017年 | 343篇 |
2016年 | 347篇 |
2015年 | 439篇 |
2014年 | 598篇 |
2013年 | 788篇 |
2012年 | 1125篇 |
2011年 | 1213篇 |
2010年 | 689篇 |
2009年 | 578篇 |
2008年 | 1090篇 |
2007年 | 1191篇 |
2006年 | 1102篇 |
2005年 | 1092篇 |
2004年 | 956篇 |
2003年 | 949篇 |
2002年 | 816篇 |
2001年 | 640篇 |
2000年 | 635篇 |
1999年 | 527篇 |
1998年 | 278篇 |
1997年 | 239篇 |
1996年 | 240篇 |
1995年 | 237篇 |
1994年 | 227篇 |
1993年 | 201篇 |
1992年 | 475篇 |
1991年 | 461篇 |
1990年 | 439篇 |
1989年 | 448篇 |
1988年 | 410篇 |
1987年 | 368篇 |
1986年 | 314篇 |
1985年 | 384篇 |
1984年 | 292篇 |
1983年 | 270篇 |
1982年 | 173篇 |
1979年 | 212篇 |
1978年 | 186篇 |
1977年 | 163篇 |
1976年 | 153篇 |
1975年 | 162篇 |
1974年 | 158篇 |
1973年 | 197篇 |
1972年 | 160篇 |
1971年 | 142篇 |
排序方式: 共有10000条查询结果,搜索用时 21 毫秒
181.
Melody Okereke Nelson Ashinedu Ukor Yusuff Adebayo Adebisi Isaac Olushola Ogunkola Eseosa Favour Iyagbaye Greatman Adiela Owhor Don Eliseo Lucero‐Prisno 《The International journal of health planning and management》2021,36(1):13-17
The COVID‐19 pandemic continues to be a major public health threat globally and low‐ and middle‐income countries (LMICs) are not an exception. The impact of the COVID‐19 pandemic is far‐reaching on many areas including but not limited to global health security, economic and healthcare delivery with a potential impact on access to healthcare in LMICs. We evaluate the impact of the COVID‐19 pandemic on access to healthcare in LMICs, as well as plausible strategies that can be put in place to ensure that the delivery of healthcare is not halted. In order to mitigate the devastating effect of the COVID‐19 pandemic on the already weak health systems in LMICs, it is much necessary to reinforce and scale up interventions and proactive measures that will ensure that access to healthcare is not disrupted even in course of the pandemic. 相似文献
182.
183.
184.
Angie S. Price Amy K. Nelson Alip Ghosh Shyamasundaran Kottilil Joel V. Chua 《Journal of medical virology》2023,95(1):e28105
Retrospective data showed that when we administered ledipasvir/sofosbuvir (LDV/SOF) to patients with hepatitis B and C coinfection, there was a modest reduction in hepatitis B surface antigen (HBsAg). Therefore, we hypothesize that similar HBsAg reduction can be seen in hepatitis B virus (HBV) monoinfected subjects. Primary and secondary efficacy endpoints are the decline in HBsAg and HBV DNA at Week 12 from baseline, respectively. We conducted an open-label Phase 2 pilot study to evaluate the safety, tolerability, and antiviral activity of LDV and/or SOF for HBV. Eligible subjects were either suppressed on antivirals (Group B) or inactive chronic HBV (Group A, C, D). Group A and B received LDV/SOF. Group C and D received SOF 400 mg and LDV 90 mg, respectively. All subjects completed the study, and all related adverse events (AEs) were mild. No discontinuations due to AEs or hepatitis flare occurred. At Week 12, HBsAg decline (log10 IU/ml) was similar between Group A (0.399) and B (0.400), less in Group C (0.207), and none in Group D, and there was HBV DNA decline in the inactive chronic HBV groups. LDV and SOF are safe and well tolerated when given to chronic hepatitis B subjects and have modest antiviral activity, particularly when given in combination. 相似文献
185.
Batalden PB Mohr JJ Nelson EC Plume SK Baker GR Wasson JH Stoltz PK Splaine ME Wisniewski JJ 《Quality management in health care》1997,5(3):41-51
Today's primary care provider faces the challenge of caring for individual patients as well as caring for populations of patients. This article offers a model--the panel management process--for understanding and managing these activities and relationships. The model integrates some of the lessons learned during the past decade as we have worked to gain an understanding of the continual improvement of health care after we have understood that care as a process and system. 相似文献
186.
187.
Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase 总被引:2,自引:0,他引:2
We have previously reported that greater than 60% of human leukemic T- cell lines possess mutations in the p53 tumor suppressor gene. To determine whether T-cell acute lymphoblastic leukemia (T-ALL) patient samples possess p53 mutations, we screened peripheral blood-and bone marrow-derived leukemia samples, taken at diagnosis and at relapse, for p53 mutations. Exons 4 through 9 and selected intron regions of the p53 gene were analyzed using polymerase chain reaction-single-strand conformation polymorphism and direct sequencing. p53 mutations were found in 0 of 15 T-ALL diagnosis samples, as compared with 10 of 36 (28%) T-ALL relapse samples. To determine whether p53 mutations play a role in the recurrence (relapse) of T-ALL, two special groups of T-ALL patients were studied: (1) a group of 8 relapse patients whose disease was refractory to chemotherapeutic treatment, and (2) a group of 6 "paired" T-ALL cell samples from patients for whom we possess both diagnosis and relapse samples. Three of 8 relapsed patients (37.5%) whose disease was refractory to the reinduction of remission by chemotherapy possessed missense mutations of the p53 gene. All 3 cases had mutations in exon 5. Among the paired samples, 3 of 6 patients harbored p53 mutations at disease recurrence, but possessed only wild- type p53 alleles at diagnosis. One case had mutation on exon 4, 1 case in exon 5, and 1 case in exon 8 with loss of heterozygosity. These data clearly indicate that recurrence of T-ALL is associated with missense mutations in p53. Our results indicate that (1) mutations of p53 do occur in T-ALL in vivo, and such mutations are associated with the relapse phase of the disease; and (2) p53 mutation is involved in the progression of T-ALL. This conclusion is supported by our observation that the introduction of T-ALL-derived mutant p53 expression constructs into T-ALL cell lines further increases their growth rate in culture, enhances cell cloning in methylcellulose, and increases tumor formation in nude mice. 相似文献
188.
189.
190.